Viviane M. Andrade
A5086923009- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV Research and Treatment
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Cervical Cancer and HPV Research
- SARS-CoV-2 detection and testing
- HIV/AIDS drug development and treatment
- Animal Virus Infections Studies
- Hepatitis B Virus Studies
- Viral Infections and Immunology Research
- Hepatitis C virus research
- Vaccine Coverage and Hesitancy
- Immune responses and vaccinations
- RNA Interference and Gene Delivery
- Click Chemistry and Applications
- Respiratory viral infections research
- HIV-related health complications and treatments
- Global Cancer Incidence and Screening
- Influenza Virus Research Studies
- Endometrial and Cervical Cancer Treatments
- Systemic Lupus Erythematosus Research
- Nutrition, Health and Food Behavior
- Bacillus and Francisella bacterial research
- Viral-associated cancers and disorders
Inovio Pharmaceuticals (United States)
2020-2025
Fundação Oswaldo Cruz
2011-2024
Imperial Consultants
2023
Hospital de Câncer de Barretos
2022
University of Miami
2017-2021
Uniabeu Centro Universitário
2019
The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of disease. We have previously engineered a synthetic DNA targeting MERS Spike (S) protein, major surface antigen coronaviruses, which currently in clinical study. Here we build on prior experience generate DNA-based candidate S protein. construct, INO-4800, results robust expression protein...
A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA (INO-4800) targeting full length spike antigen are described.INO-4800 was evaluated in two groups 20 participants, receiving either 1.0 mg or 2.0 intradermally followed CELLECTRA® EP at 0 4 weeks. Thirty-nine subjects completed both doses; one subject group discontinued trial participation prior to second dose. ClinicalTrials.gov identifier: NCT04336410.The median age 34.5, 55% (22/40) were...
Abstract Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are safe and effective as primary boosters remain urgently needed to combat the disease 2019 (COVID-19) pandemic. We describe safety durability of immune responses following doses a homologous booster dose an investigational DNA vaccine (INO-4800) targeting full-length spike antigen. Methods Three dosage strengths INO-4800 (0.5 mg, 1.0 2.0 mg) were evaluated in 120 age-stratified healthy...
In this work, a new series of arysulfonylhydrazine-1H-1,2,3-triazole derivatives were synthesized, and their ability to inhibit the in vitro replication HSV-1 was evaluated. Among 1,2,3-triazole derivatives, 1-[(5″-methyl-1″-(4‴-fluorophenylamino)-1H-1,2,3-triazol-4″-yl)carbonyl]-2-(4'-methylphenylsulfonyl)hydrazine 1-[(5'-methyl-1'-(2″,5″-dichlorophenylamino)-1H-1,2,3-triazol-4'-yl)carbonyl]-2-(phenylsulfonyl)hydrazine, with IC(50) values 1.30 1.26 μM, respectively, displayed potent...
HIV-1 persists in cellular reservoirs that can reignite viremia if antiretroviral therapy (ART) is interrupted. Therefore, insight into the nature of those may be revealed from composition recrudescing following treatment cessation. A minor population macrophage-tropic (M-tropic) viruses was identified a library recombinant constructed with individual envelope genes were obtained plasma six individuals undergoing analytic interruption (ATI). M-tropic could also enriched post-ATI using...
Summary Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has had a dramatic global impact on public health, social, and economic infrastructures. Here, we assess immunogenicity anamnestic protective efficacy in rhesus macaques of intradermal (ID)-delivered spike DNA vaccine, INO-4800. INO-4800 is an ID-delivered vaccine currently being evaluated clinical trials. Vaccination with induced T cell responses neutralizing antibody against both D614 G614 proteins. Several months...
Oregano essential oil has multiple benefits in traditional medicine, cosmetics, and food industries. Carvacrol its analog, thymol, are well-described components of oregano oil. Here, we show that these compounds inhibit HIV-target cell fusion independently viral tropism. Our results suggest carvacrol thymol alter the cholesterol content membrane, blocking HIV-1 entry into target cell. Resistance to selected for viruses with mutations envelope glycoprotein, gp41. This protein is known...
Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has had a dramatic global impact on public health and social economic infrastructures. Here, we assess immunogenicity anamnestic protective efficacy in rhesus macaques of an intradermal (i.d.)-delivered spike DNA vaccine, INO-4800, currently being evaluated clinical trials. Vaccination with INO-4800 induced T cell responses antigen RBD binding antibodies ADCP ADCD activity. Sera from animals neutralized both D614 G614...
Abstract Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global population has been vaccinated. Here we report safety and immunogenicity a DNA vaccine (INO-4800) targeting full-length Spike antigen when given to adults at high-risk exposure. Methods INO-4800 was evaluated in 401 participants randomized 3:3:1:1 ratio receive either (1 mg or 2 dose) placebo injections) intradermally (ID) followed by electroporation (EP) using CELLECTRA® 2000 Days 0 28....
Abstract Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral cellular responses against VOC in subjects immunized the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies all tested, reduced levels detected B.1.351. IFNγ T cell were fully maintained tested.
Abstract Monoclonal antibody therapy has played an important role against SARS-CoV-2. Strategies to deliver functional, antibody-based therapeutics with improved in vivo durability are needed supplement current efforts and reach underserved populations. Here, we compare recombinant mAbs COV2-2196 COV2-2130, which compromise clinical cocktail Tixagevimab/Cilgavimab, optimized nucleic acid-launched forms. Functional profiling of vivo-expressed, DNA-encoded monoclonal antibodies (DMAbs)...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune-focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses infection and Utilizing computational modeling in vitro screening, incorporated glycans into receptor-binding domain (RBD) assessed antigenic profiles. We...
Abstract Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine induced immunity. Here we compared humoral cellular responses against VOC in subjects immunized the DNA vaccine, INO-4800. INO-4800 vaccination neutralizing antibodies all tested, reduced levels detected B.1.351. IFNγ T cell were fully maintained tested.
COVID-19 remains a major public health concern. Monoclonal antibodies have received emergency use authorization (EUA) for pre-exposure prophylaxis against among high-risk groups treatment of mild to moderate COVID-19. In addition recombinant biologics, engineered synthetic DNA-encoded (DMAb) are an important strategy direct in vivo delivery protective mAb. A DMAb cocktail was synthetically encode the immunoglobulin heavy and light chains two different Fc-engineered anti-SARS-CoV-2...
Nucleic acid vaccines are designed based on genetic sequences (DNA or mRNA) of a target antigen to be expressed in vivo drive host immune response. In response the COVID-19 pandemic, mRNA and DNA SARS-CoV-2 Spike were developed. Surprisingly, head-to-head characterizations responses elicited by each vaccine type has not been performed date. Here, we have employed range preclinical animal models including hamster, guinea pig, rabbit, mouse compare delineate raised DNA, administered...
The rapid development of COVID-19 vaccines was the result decades research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well several novel changes discovery processes that partnered industry governments. And while offer potential drastically improve global health, low-and-middle-income countries around world often experience reduced access efficacy. Addressing these issues will require approaches platforms, deeper insight how mediate...
To evaluate cervical cancer screening with primary human papillomavirus (HPV) testing in Mozambique, a country one of the highest burdens globally.Women aged 30-49 years were prospectively enrolled and offered HPV using either self-collected or provider-collected specimens. Patients who tested positive for underwent visual assessment treatment inspection acetic acid to determine eligibility thermal ablation. If ineligible, they referred excision loop electrosurgical procedure, cold knife...
Abstract Here we have employed SynCon ® design technology to construct a DNA vaccine expressing pan-Spike immunogen (INO-4802) induce broad immunity across SARS-CoV-2 variants of concern (VOC). Compared WT and VOC-matched vaccines which showed reduced cross-neutralizing activity, INO-4802 induced potent neutralizing antibodies T cell responses against as well B.1.1.7, P.1, B.1.351 VOCs in murine model. In addition, hamster challenge model demonstrated that conferred superior protection...
Background: Additional SARS-CoV-2 vaccines that are safe and effective as primary boosters remain urgently needed to combat the COVID-19 pandemic. We describe safety durability of immune responses following two doses a homologous booster dose an investigational DNA vaccine (INO-4800) targeting full-length spike antigen. Methods: Three dosage strengths INO-4800 (0.5 mg, 1.0 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection followed by electroporation at 0 4...
Herpesviruses are common co-pathogens in individuals infected with human immunodeficiency virus (HIV). Herpes simplex type 1 (HSV1) enhances HIV-1 replication and has evolved mechanisms to evade or disrupt host innate immune responses, including interference interferon (IFN) signalling pathways.